Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65

1.

Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.

Ehrhardt SA, Zehner M, Krähling V, Cohen-Dvashi H, Kreer C, Elad N, Gruell H, Ercanoglu MS, Schommers P, Gieselmann L, Eggeling R, Dahlke C, Wolf T, Pfeifer N, Addo MM, Diskin R, Becker S, Klein F.

Nat Med. 2019 Oct;25(10):1589-1600. doi: 10.1038/s41591-019-0602-4. Epub 2019 Oct 7.

PMID:
31591605
2.

Modeling the Amplification of Immunoglobulins through Machine Learning on Sequence-Specific Features.

Döring M, Kreer C, Lehnen N, Klein F, Pfeifer N.

Sci Rep. 2019 Jul 24;9(1):10748. doi: 10.1038/s41598-019-47173-w.

3.

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes.

Schleimann MH, Kobberø ML, Vibholm LK, Kjær K, Giron LB, Busman-Sahay K, Chan CN, Nekorchuk M, Schmidt M, Wittig B, Damsgaard TE, Ahlburg P, Hellfritzsch MB, Zuwala K, Rothemejer FH, Olesen R, Schommers P, Klein F, Dweep H, Kossenkov A, Nyengaard JR, Estes JD, Abdel-Mohsen M, Østergaard L, Tolstrup M, Søgaard OS, Denton PW.

EBioMedicine. 2019 Jul;45:328-340. doi: 10.1016/j.ebiom.2019.07.005. Epub 2019 Jul 9.

4.

Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.

Schoofs T, Barnes CO, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP Jr, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ.

Immunity. 2019 Jun 18;50(6):1513-1529.e9. doi: 10.1016/j.immuni.2019.04.014. Epub 2019 May 21.

5.

Systematic Review And Meta-Analysis of Treatment Interruptions in HIV-1 Infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials.

Stecher M, Claßen A, Klein F, Lehmann C, Gruell H, Platten M, Wyen C, Behrens G, Fätkenheuer G, Vehreschild JJ.

Clin Infect Dis. 2019 May 18. pii: ciz417. doi: 10.1093/cid/ciz417. [Epub ahead of print]

PMID:
31102444
6.

Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.

Caskey M, Klein F, Nussenzweig MC.

Nat Med. 2019 Apr;25(4):547-553. doi: 10.1038/s41591-019-0412-8. Epub 2019 Apr 1. Review.

PMID:
30936546
7.

Antibody-mediated prevention and treatment of HIV-1 infection.

Gruell H, Klein F.

Retrovirology. 2018 Nov 16;15(1):73. doi: 10.1186/s12977-018-0455-9. Review.

8.

Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.

Khera T, Behrendt P, Bankwitz D, Brown RJP, Todt D, Doepke M, Khan AG, Schulze K, Law J, Logan M, Hockman D, Wong JAJ, Dold L, Gonzalez-Motos V, Spengler U, Viejo-Borbolla A, Ströh LJ, Krey T, Tarr AW, Steinmann E, Manns MP, Klein F, Guzman CA, Marcotrigiano J, Houghton M, Pietschmann T.

J Hepatol. 2019 Apr;70(4):593-602. doi: 10.1016/j.jhep.2018.11.003. Epub 2018 Nov 13.

PMID:
30439392
9.

Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption.

Lu CL, Pai JA, Nogueira L, Mendoza P, Gruell H, Oliveira TY, Barton J, Lorenzi JCC, Cohen YZ, Cohn LB, Klein F, Caskey M, Nussenzweig MC, Jankovic M.

Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11341-E11348. doi: 10.1073/pnas.1813512115. Epub 2018 Nov 12.

10.

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.

Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Karagounis T, Cohen YZ, Wyen C, Scholten S, Handl L, Belblidia S, Dizon JP, Vehreschild JJ, Witmer-Pack M, Shimeliovich I, Jain K, Fiddike K, Seaton KE, Yates NL, Horowitz J, Gulick RM, Pfeifer N, Tomaras GD, Seaman MS, Fätkenheuer G, Caskey M, Klein F, Nussenzweig MC.

Nat Med. 2018 Nov;24(11):1701-1707. doi: 10.1038/s41591-018-0186-4. Epub 2018 Sep 26.

11.

Combination therapy with anti-HIV-1 antibodies maintains viral suppression.

Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Lorenzi JCC, Cohen YZ, Wyen C, Kümmerle T, Karagounis T, Lu CL, Handl L, Unson-O'Brien C, Patel R, Ruping C, Schlotz M, Witmer-Pack M, Shimeliovich I, Kremer G, Thomas E, Seaton KE, Horowitz J, West AP Jr, Bjorkman PJ, Tomaras GD, Gulick RM, Pfeifer N, Fätkenheuer G, Seaman MS, Klein F, Caskey M, Nussenzweig MC.

Nature. 2018 Sep;561(7724):479-484. doi: 10.1038/s41586-018-0531-2. Epub 2018 Sep 26.

12.

LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model.

Meder L, König K, Dietlein F, Macheleidt I, Florin A, Ercanoglu MS, Rommerscheidt-Fuss U, Koker M, Schön G, Odenthal M, Klein F, Büttner R, Schulte JH, Heukamp LC, Ullrich RT.

Oncogene. 2018 May;37(20):2746-2756. doi: 10.1038/s41388-018-0158-7. Epub 2018 Mar 5.

PMID:
29503447
13.

Progress in HIV-1 antibody research using humanized mice.

Gruell H, Klein F.

Curr Opin HIV AIDS. 2017 May;12(3):285-293. doi: 10.1097/COH.0000000000000368. Review.

PMID:
28422792
14.

Early antibody therapy can induce long-lasting immunity to SHIV.

Nishimura Y, Gautam R, Chun TW, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M, Donau OK, Plishka RJ, Buckler-White A, Seaman MS, Lifson JD, Koup RA, Fauci AS, Nussenzweig MC, Martin MA.

Nature. 2017 Mar 23;543(7646):559-563. doi: 10.1038/nature21435. Epub 2017 Mar 13.

15.

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.

Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY, Learn GH, Cohen YZ, Lehmann C, Gillor D, Shimeliovich I, Unson-O'Brien C, Weiland D, Robles A, Kümmerle T, Wyen C, Levin R, Witmer-Pack M, Eren K, Ignacio C, Kiss S, West AP Jr, Mouquet H, Zingman BS, Gulick RM, Keler T, Bjorkman PJ, Seaman MS, Hahn BH, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC, Klein F.

Nat Med. 2017 Feb;23(2):185-191. doi: 10.1038/nm.4268. Epub 2017 Jan 16.

16.

Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy.

Caskey M, Klein F, Nussenzweig MC.

N Engl J Med. 2016 Nov 24;375(21):2019-2021. Epub 2016 Nov 9. No abstract available.

PMID:
27959740
17.

Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.

Gristick HB, von Boehmer L, West AP Jr, Schamber M, Gazumyan A, Golijanin J, Seaman MS, Fätkenheuer G, Klein F, Nussenzweig MC, Bjorkman PJ.

Nat Struct Mol Biol. 2016 Oct;23(10):906-915. doi: 10.1038/nsmb.3291. Epub 2016 Sep 12.

18.

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.

Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T, Shimeliovich I, Patel R, Burke L, Cohen YZ, Hadrigan S, Settler A, Witmer-Pack M, West AP Jr, Juelg B, Keler T, Hawthorne T, Zingman B, Gulick RM, Pfeifer N, Learn GH, Seaman MS, Bjorkman PJ, Klein F, Schlesinger SJ, Walker BD, Hahn BH, Nussenzweig MC, Caskey M.

Nature. 2016 Jul 28;535(7613):556-60. Epub 2016 Jun 22.

19.

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T, Lorenzi JC, Parrish EH, Learn GH, West AP Jr, Bjorkman PJ, Schlesinger SJ, Seaman MS, Czartoski J, McElrath MJ, Pfeifer N, Hahn BH, Caskey M, Nussenzweig MC.

Science. 2016 May 20;352(6288):997-1001. doi: 10.1126/science.aaf0972. Epub 2016 May 5.

20.

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.

Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, Golijanin J, Buckler-White A, Sadjadpour R, Wang K, Mankoff Z, Schmidt SD, Lifson JD, Mascola JR, Nussenzweig MC, Martin MA.

Nature. 2016 May 5;533(7601):105-109. doi: 10.1038/nature17677. Epub 2016 Apr 27.

Supplemental Content

Loading ...
Support Center